APX-003 is under clinical development by Apexigen and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect APX-003’s likelihood of approval (LoA) and phase transition for Wet (Neovascular / Exudative) Macular Degeneration took place on 29 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APX-003 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

APX-003 overview

APX-003 (BD0801, Sevacizumab) is under development for the treatment of transitional cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, non-small cell lung cancer, peritoneal cancer, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and Barcelona clinical liver cancer (BCLC), clear cell adenocarcinoma, endometriod adenocarcinoma, malignant Brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma and undifferentiated carcinoma, metastatic colorectal cancer and wet age-related macular degeneration. The drug candidate is administered through intravitreal route and parenteral route. It is a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). It is based on RabMab technology.

Apexigen overview

Apexigen is a clinical-stage biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of cancer. The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell responses. It also provides other immune oncology drug candidates that are in pre clinical stage of development. The company develops pipeline products using its APXiMAB, a proprietary antibody discovery platform. The company’s products include APX601, APX701 and APX201 of Internal Oncology Programs. The company works in strategic collaboration with various pharmaceutical companies to develop drugs for the treatment of cancer and inflammation, among others. Apexigen is headquartered in San Carlos, California, the US.

Quick View APX-003 LOA Data

Report Segments
  • Innovator
Drug Name
  • APX-003
Administration Pathway
  • Intravitreal
  • Parenteral
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.